This site uses cookies to store information on your computer. Learn more x

Latest Results & Outlook

Full Year 2017 Highlights

  • Strong performance in Q4, contributing to an excellent year
  • Sales up 9% to €8,632m, with 9% organic growth mainly from volume growth
  • Adjusted EBITDA up 15% to €1,445m, driven by both Nutrition and Materials
  • ROCE up 190 bps to 12.3%
  • Adjusted net profit up 36% to €706m
  • Total net profit of €1,781m, including gain on Patheon disposal of €1,250m
  • Proposed dividend increase from €1.75 to €1.85 per ordinary share
  • Full year outlook 2018 above Strategy 2018 targets

Key figures and indicators

Key figures and indicators

in € million FY 2017 FY 2016 % change
vol. price /mix FX
other
Sales 8,632 7,920 9% 7% 2% -1% 1%
Nutrition 5,579 5,169 8% 7% 1% 0% 0%
Materials 2,825 2,513 12% 7% 6% -2% 1%
Adj. EBITDA1 1,445 1,262 15%        
Nutrition 1,053 931 13%        
Materials 488 435 12%        
EBITDA (cont. ops.) 1,348 1,174          
ROCE (%) 12.3% 10.4%          

1) Adjusted EBITDA (and Adjusted net profit) are Alternative Performance Measures (APMs) that reflect continuing operations.
See page 17 for definition and reconciliation

CEO statement

“We are delighted to report again an excellent year, as we significantly exceeded our Strategy 2018 targets for EBITDA, ROCE and organic sales growth. Our focus on driving above market growth while relentlessly pursuing efficiency initiatives and maintaining capital discipline continues to produce very good results in both Nutrition and Materials.

Our success comes from the ability to deliver sustainable, innovative solutions to meet our customers’ demand and help them to address end-market needs. Furthermore, we have taken next steps in embedding the organizational agility and culture that we seek within our company. We are firmly on track with our cost-reduction and efficiency improvement programs. In addition, we successfully divested our share in Patheon ahead of schedule, creating significant value. With all of these developments ahead of plan we brought forward our regular strategic review process for the period beyond 2018.

We remain relentlessly focused on improving our operational and financial performance through our growth initiatives and by completing the final stage of our improvement programs. These actions should allow us to continue our above-market growth and further improve our financial returns and capital efficiency. We expect to deliver above our Strategy 2018 targets in 2018.”

Outlook 2018

DSM expects to deliver full-year 2018 results above the targets set in Strategy 2018, with an Adjusted EBITDA growth somewhat up from high single-digit to double-digit and a ROCE growth above 100 basis points. The expected substantial negative foreign exchange effects, based on current rates, will be more than offset by a positive pricing environment in Nutrition, part of which is temporary in nature and expected to be heavily weighted towards the first half of the year.

Q4 Highlights

  • DSM reports another strong quarter
  • Sales up 8% to €2,176m, with 12% organic growth, driven by volumes and prices
  • Adjusted EBITDA up 14% to €359m
  • Nutrition: 13% organic sales growth; Adjusted EBITDA up 12%
  • Materials: 5% volume growth; Adjusted EBITDA up 13%

Key figures and indicators

in €
million
Q4 2017 Q4 2016 % change
vol. price
/mix
FX
other
Sales 2,176 2,015 8% 7% 5% -5% 1%
Nutrition 1,428 1,321 8% 9% 4% -6% 1%
Materials 693 639 8% 5% 7% -4% 0%
Adj. EBITDA1 359 315 14%        
Nutrition 267 238 12%        
Materials 119 105 13%        
EBITDA (cont. ops.) 316 270          
ROCE (%)2 12.3% 10.4%          

1) Adjusted EBITDA (and Adjusted net profit) are Alternative Performance Measures (APMs) that reflect continuing operations.
See page 17 for definition and reconciliation
2) Full year 2017

Key figures and indicators

in € million FY 2017 FY 2016 % change
vol. price
/mix
FX
other
Sales 8,632 7,920 9% 7% 2% -1% 1%
Nutrition 5,579 5,169 8% 7% 1% 0% 0%
Materials 2,825 2,513 12% 7% 6% -2% 1%
Innovation Center 169 167          
Corporate Activities 59 71          
in € million Q4 2017 Q4 2016 % change
vol. price/
mix
FX
other
Sales 2,176 2,015 8% 7% 5% -5% 1%
Nutrition 1,428 1,321 8% 9% 4% -6% 1%
Materials 693 639 8% 5% 7% -4% 0%
Innovation Center 43 41          
Corporate Activities 12 14          
in €
million
FY 2017 FY 2016 % change
Q4 2017 Q4 2016
% change
Sales 8,632 7,920 9% 2,176 2,015 8%
Adjusted EDITDA1 1,445 1,262 15% 359 315 14%
Nutrition 1,053 931 13% 267 238 12%
Materials 488 435 12% 119 105 13%
Innovation Center 9 1   4 -1  
Corporate Activities -105 -105   -31 -27  
Adjusted EBITDA margin1 16.7% 15.9%   16.5% 15.6%  
EBITDA1 1,348 1,174   316 270  
Adjusted EBIT1 957 791 21% 240 190 26%
EBIT1 846 685   199 139  
Capital Employed1 7,766 7,889        
Average Capital Employed1 7,776 7,627        
ROCE (%) 12.3% 10.4%        
Effective tax rate2 16.8% 18.3%        
Adjusted net profit1,3 706 520 36% 202 130 55%
Net profit - Total DSM
1,781 629 183% 178 87 105%
Adjusted net EPS1
3.92 2.90 35% 1.11 0.73 52%
Net EPS - Total DSM 10.07 3.52   0.98 0.48  
Operating cash flow 996 1,018 -2% 377 374 1%
Capital Expenditures4 546 475   162 170  
Net debt 742 2,070        

1) Continuing operations
2) Over Adjusted taxable result
3) Including result attributed to non-controlling interest
4) Cash, net of customer funding

In this report:
Organic sales growth’ is the total impact of volume and price/mix;
'Total Working Capital’ refers to the total of ‘Operating Working Capital’ and ‘non-Operating Working Capital’

Strategy 2018: Driving Profitable Growth

Stepping up DSM’s financial performance

DSM’s Strategy 2018: Driving Profitable Growth is focused on ensuring that the potential of the business portfolio that has been created over recent years is translated into improved financial results. Reflecting its disciplined focus on performance, DSM has implemented a three-year strategic period with two headline financial targets: high single-digit percentage annual Adjusted EBITDA growth and high double-digit basis point annual ROCE growth.

In 2017, we delivered well ahead of our original ambitions for the second year in a row:

Two headline financial targets High single-digit percentage annual Adjusted EBITDA growth High double-digit basis point annual ROCE growth
Achievements to date: 2016: 17%
2017: 15%
2016: 280 bps
2017: 190 bps

DSM has defined clear actions to achieve its targets, including outpacing market growth, cost reduction and efficiency improvement programs and making a continuous push for consistent improvements in capital efficiency.

Clear actions identified to achieve targets Businesses aim to outpace market growth in all segments €250-300m cost reduction and efficiency improvements Consistent improvements in capital efficiency
Achievements to date: Nutrition organic growth
2016: 5%
2017: 8%

Materials volume growth
2016: 4%
2017: 7%
2017 achievements:
Cumulative savings on track (about €195m run rate at the end of 2017)
2017 achievements:
Cash from operating activities at €996m.
Capex at €546m, within guidance of €500-550m.
Total Working Capital at 17.2%, aspiration level <20%.

Outpaced market growth
DSM has outpaced market growth in 2016 and in 2017 delivering strong organic growth in both Nutrition and Materials, growing at rates around double the markets it operates in. DSM continued to leverage its innovation capabilities together with market insights and close customer relationships to accelerate growth for its solutions in its key segments and to develop and open new segments. DSM also took further steps on promising innovation projects for future growth with a wider societal impact, such as Clean Cow, Green Ocean (now called Veramaris), Stevia and Niaga. Sales to High Growth Economies increased in line with the higher sales in 2017. It remained stable at 44% of total sales, in line with our aspirations, providing a well-balanced geographical spread of our sales. Sales to China increased from 12% to 13% of total sales.

Cost-reduction and improvement programs
DSM has instigated extensive cost-reduction and improvement programs which were targeted to deliver €250-300 million versus the 2014 baseline. In 2017, all of these well-identified programs progressed as planned and the programs are on track to deliver the targeted benefits. DSM achieved run-rate cumulative cost savings of about €195 million at the end of 2017. We expect to achieve run-rate cumulative savings of between €270 million and €280 million for the total program at the end of 2018. The 2017 one-time costs related to the improvement programs amount to €60 million with roughly €30 million to go in 2018 to complete the program. In support of our targets, we adjusted our global organizational and operating model to create a more agile, commercially focused and cost-efficient company.

Additional actions underpinning Strategy 2018

Besides stepping up the financial performance of DSM’s businesses, Strategy 2018 comprises additional elements aimed at future-proofing the company, providing a sustainable basis for long-term value creation for all its stakeholders.

For DSM, sustainability is a core value as well as a key business driver. Our growth platforms are addressing important societal trends and have in particular strong alignment with 5 of the 17 United Nations Sustainable Development Goals (SDG’s also referred to as global goals), which together in fact set out the strategy for the world. In doing so, DSM focuses on delivering science-based, sustainable and scalable solutions that not only help address challenges the world faces but also positively impact the value chain. These ‘Brighter Living Solutions’ offer higher growth rates and better margins.

DSM continued to make good progress toward its sustainability aspirations in 2017:

  • The ‘Brighter Living Solutions’ amounted to 62% of sales, on track towards our ambitious aspirations.
  • DSM’s drive to improve its environmental efficiency is on track, with further improvements in both greenhouse-gas efficiency (26% versus 2008) and energy efficiency (3% versus 2015) in 2017.
  • The company now sources about a fifth of its purchased electricity from renewable sources and is on track to reach its goal of 50% by 2025.
  • Employee engagement jumped from 71% to 75% according to the Employee Engagement Index, which indicates how our employees feel in terms of commitment, pride, advocacy, and satisfaction.
  • The Frequency Index of all DSM Recordable Injuries increased from 0.33 to 0.36, due to a relative increase in the number of incidents in the first months of 2017. This increase and a fatal incident in the latter part of the year stresses the paramount importance of continued safety programs as we aspire to be an incident-free company.

Many of the above-mentioned achievements are being recognized externally as well, resulting in leading positions in, amongst others, CDP, Dow Jones Sustainability Index (DJSI) and Sustainalytics.

DSM has adjusted its global organization and operating model to support the company’s growth and to create a more agile, commercially-focused and cost-efficient business. Actions such as the implementation of new more globally leveraged target operating models in ICT, Finance, HR, Indirect Sourcing, Communication and Legal are all completed. The emphasis at this stage is above all on ensuring that cost savings, as well as the new way of working are anchored in the organization and in supporting mindset and behaviors.

Talent management and development is a further strategic cornerstone. DSM continued to invest in its talent pipeline to ensure it can sustainably address future challenges and demands. It also finalized the roll-out of a new learning and development program called Lead & Grow for all executives.

Inclusion & Diversity is an important enabler for a high-performing organization and DSM continues to strive to achieve a balanced and representative workforce. Today, more nationalities are represented across DSM and there is a better gender balance across different levels of our organization, including more women in executive positions (from 15% in 2016 to 17% in 2017). The composition of our Supervisory Board also reflects our desire to be more gender balanced, international, inclusive and diverse.

DSM monetized the partnership established for its former pharma activities with the sale of its remaining stake in Patheon to Thermo Fisher Scientific Inc., realizing over recent years total proceeds of approximately €2 billion, of which €1.5 billion in 2017 with a gain on disposal of €1,250 million.

DSM strengthened its portfolio through smaller acquisitions. Key highlights include:

  • Twilmij: acquisition of a Dutch feed premix company
  • UP4® brand: acquisition in probiotics for consumer health
  • Inner Mongolia Rainbow Biotechnology: acquisition of a majority stake in hydrocolloid for human nutrition
  • BioCare®: acquisition in probiotics for consumer health
  • Amyris: acquisition of Amyris’ production facility in Brazil for bio-based farnesene Furthermore, DSM made an equity investment in Amyris and entered into a development arrangement for bio-based nutritional ingredients
  • Sunshine: acquisition of a solar photovoltaic (PV) backsheet technology

DSM is building for further sales and adjusted EBITDA growth beyond 2018 through Innovation. DSM made good progress. Innovation Sales were 21% against our ambitious aspiration of 20% and DSM further focused its innovation program on a smaller number of bigger projects providing interesting opportunities from 2019/2020 and onwards. Examples include:

  • The Clean Cow project; feed additives for reduced methane emissions in cattle
  • The Green Ocean partnership with Evonik (now called Veramaris) for algae-based omega-3 for sustainable aquaculture
  • The fermentative stevia sweetener platform
  • Plant-based proteins for human nutrition
  • Sustainable biological solutions for crop protection in agriculture
  • Niaga® Technology for fully-recyclable carpets
  • ForTii® high-performance plastics
  • Dyneema® carbon composites

Furthermore, DSM strengthened its innovation infrastructure through the establishment of two state-of-the-art R&D centers, one in Biotechnology and one in Materials Sciences.

Review by Cluster

Nutrition

in €
million
FY 2017 FY 2016 % change
Q4 2017
Q4 2016 % change
Sales 5,579 5,169 8% 1,428 1,321 8%
Adjusted EBITDA 1,053 931 13% 267 238 12%
Adjusted EBITDA margin (%) 18.9% 18.0%   18.7% 18.0%  
Adjusted EBIT 770 645 19% 195 160 22%
Capital Employed 5,420 5,537        
Average Capital Employed 5,447 5,375        
ROCE (%) 14.1% 12.0%        
Total Working Capital 1,339 1,414        
Average Total Working Capital as % of Sales 26.6% 28.1%        

Nutrition is outperforming its aspirations as outlined in Strategy 2018. The business continued its strong momentum, delivering clearly above market growth with an increasingly higher-value portfolio of feed and food solutions. The nutrition improvement programs, covering cost reductions, operational and sales excellence, continued to underpin ongoing progress.

Full year 2017 sales increased by 8% organically when compared to 2016, led by volumes up 7% and prices up 1%. The successful implementation of the growth initiatives continued to drive organic growth, both in Animal Nutrition and Human Nutrition, clearly outpacing market growth.

Full year 2017 Adjusted EBITDA was €1,053 million, up 13% driven by organic sales growth in combination with the impact of the cost savings and efficiency improvement programs. This increase in Adjusted EBITDA equals the very strong 2016, when Adjusted EBITDA also grew by 13%. The Adjusted EBITDA margin of 18.9% further improved in 2017 compared with 18.0% in 2016.

Q4 2017 sales were 8% up on prior year with 13% organic growth partly offset by a 6% negative currency effect. The 9% higher volumes were driven by good growth in all businesses with an exceptionally strong performance in Animal Nutrition. The 4% price increase was largely the result of higher premix and vitamin prices.

Q4 2017 Adjusted EBITDA was up 12% compared to Q4 2016, driven by a combination of strong organic sales growth and the impact of improvement programs. This increase was achieved despite a negative development in currencies. The Adjusted EBITDA margin was 18.7%, a solid increase versus 18.0% in Q4 2016.

Animal Nutrition & Health

Full year 2017 sales were exceptionally strong, with 11% organic growth, driven by 9% volume growth, albeit against an easy comparative base. The business continued to benefit from its strategy to address a wide range of species, as well as from its diversified geographical presence, covering all the major growth areas in the world, and its strong forward-integrated premix position. Markets in animal feed were favorable and supportive in 2017, except for Latin America, where weak economic conditions impacted domestic demand. Prices were 2% above 2016, owing to higher premix and vitamin prices.

Q4 2017 organic growth was exceptionally high at 18%. The reported 12% volume growth against an undemanding comparison base, resulted from a combination of very strong sales in Brazil, strong premix sales in all regions reflecting continued strong global demand, and higher vitamin sales. The high demand for the export beef markets in Brazil continued in Q4 2017. This was accentuated by additional sales in anticipation of an ERP system change in January 2018 at Tortuga. The supply shortages in vitamin E and vitamin A from outages at some large European producers have resulted in some additional deliveries to our existing -contracted- premix customers as well as emergency spot businesses with other accounts.

The reported 6% price effect resulted largely from a mix effect driven by the exceptionally strong premix and Tortuga sales. Towards the end of the quarter, DSM also benefitted from somewhat higher vitamin A and E prices for emergency spot business.

Human Nutrition & Health

Full year 2017 sales were up 6%, led by 7% organic growth. After a significant step-up in organic growth in 2016, the business maintained its positive momentum with 6% volume growth and a slightly positive price development, despite ongoing softness in some of its end-market segments. The growth initiatives we embarked on under Strategy 2018 resulted in this above market growth.

Food & beverage markets are being successfully addressed through tailored premixes and the business moving closer to regional and local customers. Growth in dietary supplements is driven by sales excellence programs, the introduction of new multi-vitamins and omega-3 solutions and continued double-digit growth in i-Health which benefitted from the recent expansion into China. Overall, the business has moved closer to the consumer, with more than 40% of revenues coming from custom nutrient premixes, retail-ready solutions, and the i-Health consumer products. Early life nutrition remained a solid performer despite the volatility in China due to new regulations.

Overall, prices were stable, with higher prices for advanced formulations and premixes compensating for somewhat lower contractual prices in early life nutrition.

Q4 2017, showed strong organic growth driven by volumes (+5%) and price/mix (+4%). Volume growth continued to be good in all segments. The positive price effect resulted from a combination of a favorable mix of strong performance in premixes, early life nutrition and i-Health, and some benefits from higher prices for premix and advanced formulations. Vitamin C prices were positively impacted by supply restrictions due to the enforcement of environmental regulations in China, an event which in part could prove to be temporary.

Food Specialties

FY 2017 sales were up 1% versus 2016 with an organic growth of 3%, driven by a solid performance in hydrocolloids, savory ingredients, bio-preservation, food & crop protection, cultures and enzymes. The latter was hampered by some capacity constraints and therefore not able to fully benefit from strong demand. Initiatives to expand capacity and optimize supply are underway. Savory Ingredients had a strong year driven by strong demand for its portfolio of yeast extracts, process flavors, and taste modulators to provide an enjoyable taste experience in low-sugar, low-salt, and low-fat applications.

In 2018 DSM will re-evaluate its control assumption over Yantai Andre Pectin which could result in de-consolidation of the entity. The re-evaluation is triggered by recent developments around the refusal of the other shareholders to transfer their shares to DSM, despite an earlier agreement. In 2017 the consolidated sales were €47 million and Adjusted EBITDA was €17 million.

Personal Care & Aroma Ingredients

FY 2017 sales were up 5% versus 2016 with an organic growth of 6%, driven by good performance in all product lines (sun-, skin- and hair care, and aroma ingredients) supported by accelerated innovation and stronger customer relationships. Aroma ingredients had a very strong Q4 sales due to competitor supply outages.

Materials

in €
million
FY 2017 FY 2016 % change
Q4 2017
Q4 2016 % change
Sales 2,825 2,513 12% 693 639 8%
Adjusted EBITDA 488 435 12% 119 105 13%
Adjusted EBITDA margin (%) 17.3% 17.3%   17.2% 16.4%  
Adjusted EBIT 361 311 16% 86 77 12%
Capital Employed 1,786 1,807        
Average Capital Employed 1,809 1,772        
ROCE (%) 20.0% 17.6%        
Total Working Capital 323 280        
Average Total Working Capital as % of Sales 12.2% 12.5%        

Materials delivered another year of strong financial performance, continuing its excellent progress since the start of Strategy 2018. The ‘silent transformation’ of the materials portfolio through a differentiated approach focusing on specialty products, provides a clear framework to outpace market growth and supported the cluster's performance again in 2017. Growth continued to be driven by demand for more sustainable, innovative lightweight, environmentally friendlier, safer, and high-performing solutions.

Full year 2017 sales were up 12% versus the same period last year. Strong growth in specialties was the main driver behind the 13% organic growth, of which 7% was volume growth. The 6% price effect reflected increased input costs. All three businesses in Materials delivered a double-digit percentage organic growth.

  • DSM Engineering Plastics continued to successfully shift its portfolio toward higher-value, sustainable, specialty materials aimed at electrics & electronics and automotive applications, markets within which DSM has a strong position. DSM made good progress with its aim to further reduce its exposure to the polyamide-6 extrusion markets, by optimizing its US manufacturing footprint and by focusing on its captive specialty compounds and higher-end applications such as food packaging.
  • DSM Resins & Functional Materials continued to benefit from strong demand for non-solvent based coating solutions. Strong growth in powder and waterborne coating resins was driven by healthy demand in the global building and construction markets, as well as Chinese demand for environmentally-friendly waterborne coatings for maritime container coatings. The IP-protected functional materials once again delivered strong growth especially driven by the healthy demand for fiber-optic materials for 4G infrastructures.
  • DSM Dyneema delivered strong growth in personal protection and commercial marine markets in which Dyneema is well recognized for its innovative, unique, and patent-protected technologies.

Full year 2017 Adjusted EBITDA increased by 12% versus 2016, driven by higher volumes. The Adjusted EBITDA margin was stable at 17.3% as pricing and group-wide cost savings and efficiency improvement programs offset higher input costs and negative foreign currency effects. This robust financial performance demonstrates the improvements achieved in the quality of returns in Materials over recent years.

Q4 2017 sales were up 12% organically with 5% higher volumes and 7% higher prices, reflecting the increase in input costs. All three businesses delivered double-digit percentage organic growth in Q4 2017.

The powder coating resins plant in Augusta (US) remained closed in Q4 because of the tragic accident at the end of September 2017. Nevertheless, owing to its global manufacturing footprint, DSM’s US customers continued to be supplied. DSM expects the Augusta plant to start up again at the end of Q1 2018.

Q4 2017 Adjusted EBITDA was up 13% compared to Q4 2016, driven by good volume growth and efficiency improvements and despite weaker currencies as well as higher input costs during the quarter, causing some margin pressure in our resins business. The Adjusted EBITDA margin was 17.2%, versus 16.4% in Q4 2016, as the effects of negative currency effects and higher raw materials costs, were offset by higher prices and cost savings.

Innovation Center

in €
million
FY 2017 FY 2016 % change
Q4 2017
Q4 2016 % change
Sales 169 167 1% 43 41 5%
Adjusted EBITDA 9 1   4 -1  
Adjusted EBIT -30 -24   -1 -9  
Capital Employed 562 576        

The Innovation Center made good progress over the year delivering on its Strategy 2018 goals to extract value from the Emerging Business Areas, the acceleration of large innovation projects, while simultaneously supporting the Nutrition and Materials business with their growth initiatives.

Full year 2017 sales in the main Emerging Business Area DSM Biomedical showed a strong underlying growth, largely offsetting the gradual discontinuation of a large contract during the year. DSM Advanced Solar delivered good growth in antireflective coatings and through the new backsheet activities for solar panels which were added in 2017 through the Sunshine acquisition.

The full year 2017 Adjusted EBITDA increase was largely driven by one-time positive effects from restructurings in DSM Advanced Solar which had a positive EBITDA effect due to releases of acquisition related liabilities, whereas the redundancy of certain assets related to these restructurings led to an impairment loss impacting the EBIT negatively.

Corporate Activities

in €
million
FY 2017 FY 2016 Q4 2017
Q4 2016
Sales 59 71 12 14
Adjusted EBITDA -105 -105 -31 -27
Adjusted EBIT -144 -141 -40 -38

Full year 2017 Adjusted EBITDA stayed in line with last year mainly as a result of the contribution of the cost savings programs being offset by the impact of the Augusta incident on DSM’s captive insurance company.

Joint Ventures and Associates

Financial overview of DSM’s key joint ventures and associates

in €
million
FY 2017 FY 2016 % change Q4 2017 Q4 2016 % change
DSM Sinochem            
Sales 440 431 2% 119 102 17%
Adjusted EBITDA% 17% 14%   23% 15%  
ChemicaInvest            
Sales
1,933 1,802 7% 458 502 -9%
Adjusted EBITDA% 11% 6%   15% 13%  
  • DSM Sinochem Pharmaceuticals (50% DSM) - continued to deliver strong growth over the year as its sustainability-driven antibiotics platforms are increasingly valued by the market. Sales growth was partly offset by negative foreign currency effects. Q4 was a strong quarter.
  • ChemicaInvest (35% DSM) - showed a very good financial recovery driven by favorable conditions in the caprolactam market combined with an improved cost structure and lean operational management. Lower sales in Q4 2017 compared to Q4 2016 were due to the closure of the caprolactam plant in the US.

Net result contribution of joint ventures / associates

in €
million
FY 2017 FY 2016 Q4 2017 Q4 2016
DSM Sinochem (50%) 9 6 5 1
Patheon1   7 10 0 16
ChemicaInvest2 (35%) 5 -9 5 0
Other associates / joint ventures -25 -25 -7 -13
Total before APM adjustments -4 -18 3 4
APM adjustments 1,158 212 6 -5
Share of the profit of associates / joint ventures   1,154 194 9 -1

1) DSM’s share in Patheon was 49% in H1 2016, and 33.5% up until 15 May 2017. DSM completed the divestment of its share in Patheon on 29 August 2017.
2) DSM only recognized the part of its share in the 2017 positive result of ChemicaInvest that exceeded the zero-equity value. DSM has not recognized losses below zero as DSM has no obligation to fund beyond its net interest.

The following APM adjustments were included in the full year 2017 result of joint ventures and associates:

  • On 29 August 2017, the shares in Patheon N.V. were sold to Thermo Fisher Scientific Inc. resulting in a book profit of €1,250 million.
  • Over the year, DSM made other various APM adjustments of €92 million, mostly related to impairments of assets of associates, including POET-DSM for €65 million.

Cash Flow, Capital Expenditures and Financing

in €
million
FY 2017 FY 2016 Q4 2017 Q4 2016
Cash from Operating Activities 996 1,018 377 374
Total Working Capital
1,499 1,481    
Total Working Capital as % of Sales 17.2% 18.4%    
Capital Expenditure (cash, net of customer funding) 546 475 162 170
Net Debt (end of period)   742 2,070    

Cash flow from operating activities amounted to €996 million for the year 2017, which was slightly below the comparative period in 2016. Cash-wise, the OWC increased by €195 million reflecting strong organic growth. This negatively impacted the cashflow. In absolute terms OWC was stable in 2017 as the increase of OWC related to organic growth (9%) was largely compensated by the weakening of mainly USD and CHF. The OWC percentage improved from 23.9% end of 2016 to 22.3% end of year 2017.

Total Working Capital amounted to €1,499 million at the end of 2017 compared to €1,481 million at the end of 2016. Working capital as a percentage of sales amounted to 17.2%, being an improvement of 1.2% compared to year-end 2016 and well below our aspiration of lower than 20%.

Net debt was €742 million compared to €2,070 million end of 2016. The decrease of €1,328 million was mainly due to the proceeds from the sale of Patheon shares in total of €1,535 million.

The reported effective tax rate was 16.8% over Adjusted taxable result 2017 (2016: 18.3%). This decrease was mainly caused by a one-time benefit from the US tax reform. As from 2018, this tax reform, being a combination of a decreased US federal tax rate from 35% to 21% and a broadening of the tax base, will have a net positive effect of approximately 1%. Overall however, the Group effective tax rate is expected to remain within the 18-20% range.

Proposed dividend

DSM’s dividend policy is to provide a stable and preferably rising dividend. Reflecting its confidence in the financial performance of the company, DSM proposes to increase the dividend from €1.75 to €1.85 per ordinary share for 2017. This will be proposed to the Annual General Meeting of Shareholders to be held on 9 May 2018. An interim dividend of €0.58 per ordinary share having been paid in August 2017, the final dividend payment would then amount to €1.27 per ordinary share.

The dividend will be payable in cash or in the form of ordinary shares at the option of the shareholder, with a maximum of 40% of the dividend amount available for stock dividend. If more than 40% of the dividend is requested by the shareholders to be paid in shares, those shareholders who have chosen to receive their dividend in shares will receive their stock dividend on a pro-rata basis, the remainder being paid out in cash. Dividend in cash will be paid after deduction of 15% Dutch withholding tax. The ex-dividend date is 11 May 2018.

Overview of Alternative Performance Measures (APM) adjustments to EBIT(DA)

In presenting and discussing DSM’s financial position, operating results and cash flows, management uses certain alternative performance measures not defined by IFRS. These alternative performance measures should not be viewed in isolation as alternatives to the equivalent IFRS measures and should be used as supplementary information in conjunction with the most directly comparable IFRS measures. Alternative performance measures do not have standardized meaning under IFRS and therefore, may not be comparable to similar measures presented by other companies. For DSM, the most important APM is the application of APM adjustments to the IFRS measures to provide clear reporting on the underlying business developments.

The following overview gives a summary of APM adjustments (for reconciliation see page 19 & 21).

APM adjustments full year 2017:

Nutrition: EBITDA adjustments amounted to -€31 million of which -€19 million relating to the profit improvement programs, -€9 million site-closure costs and -€3 million acquisition related costs. EBIT adjustments amounted to -€42 million including -€11 million asset impairment.

Materials: EBITDA adjustments amounted to -€2 million of which -€3 million relating to site closure costs and +€1 million relating to the release of a litigation provision. EBIT adjustments amounted to +€7 million including +€9 million reversal of an asset impairment.

Innovation Center: EBITDA adjustments amounted to zero as +€1 million relating to the release of a restructuring provision was offset by -€1 million acquisition costs. EBIT adjustments amounted to -€11 million including -€11 million asset impairment.

Corporate Activities: EBITDA adjustments amounted to -€64 million of which -€42 million related to restructuring programs, -€15 million relating to a provision for demolition costs and -€7 million related to the spin-off of some research activities. EBIT adjustments amounted to -€65 million including -€1 million asset impairment.

APM adjustments Q4 2017:

Nutrition: EBITDA adjustments amounted to -€17 million of which -€5 million relating to the profit improvement programs, -€3 million acquisition related costs and -€9 million site closure costs. EBIT adjustments amounted to -€24 million including -€7 million asset impairment.

Materials: EBITDA adjustments amounted to -€3 million relating to site closure costs. EBIT adjustments amounted to +€6 million including +€9 million reversal of an asset impairment.

Corporate Activities: EBITDA adjustments amounted to -€23 million (EBIT -€23 million) of which -€15 million relating to a provision for demolition costs and -€8 million related to restructuring programs.